The specific mechanism involves the inhibition of nuclear factor-κB (NF-κB) activity in gastric cancer cells after treatment with METase, resulting in the upregulation of tumor-necrosis-factor-associated apoptosis-inducing ligand (TRAIL) expression and the subsequent downregulation of P-gp. The gene discussed is NFKB1; the disease is gastric cancer.